A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
← catalyst calendarNCT07623200 · readout in 1,031 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
426estimated
Sites
180
Countries
Australia, Austria, Belgium +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-08 | estimated | When the study began enrolling |
| Primary completion | 2029-06-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Essential Thrombocythemia
Interventions
- Drug: INCA033989
- Drug: Best Available Treatment — also filed as BAT could include:, • HU, • ANA, • PEG interferon alfa-2a, • Ropeginterferon alfa-2b
Primary outcome
what the primary-completion date above is the date OFDurable clinicohematologic response (DCR)
measured Week 24
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed